Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

Affiliations

¹ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.
² Skinflammation Center, Hamburg, Germany, Dermatologikum Berlin, Berlin, Germany.
³ School of Medicine, Imperial College London, U.K.
⁴ Dermatologikum Hamburg, Hamburg, Germany.
⁵ Psoriasis-Centre, Department of Dermatology, University Medical Centre Schleswig-Holstein, Kiel, Germany.
⁶ Company for Medical Study & Service, Selters, Germany.
⁷ Department of Dermatology and Allergology, University of Ulm, Germany.
⁸ Hautzentrum im Jahrhundert Haus - Centre for Clinical Trials, Bochum, Germany.
⁹ Hautarztpraxis Lübeck, Lübeck, Germany.
¹⁰ Dermatological Sciences, University of Manchester, Manchester, U.K.

Clinical Trial

K Reich et al. Br J Dermatol. 2019 Oct.

. 2019 Oct;181(4):859-862.

doi: 10.1111/bjd.18001. Epub 2019 Jul 1.

¹ Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany.
² Skinflammation Center, Hamburg, Germany, Dermatologikum Berlin, Berlin, Germany.
³ School of Medicine, Imperial College London, U.K.
⁴ Dermatologikum Hamburg, Hamburg, Germany.
⁵ Psoriasis-Centre, Department of Dermatology, University Medical Centre Schleswig-Holstein, Kiel, Germany.
⁶ Company for Medical Study & Service, Selters, Germany.
⁷ Department of Dermatology and Allergology, University of Ulm, Germany.
⁸ Hautzentrum im Jahrhundert Haus - Centre for Clinical Trials, Bochum, Germany.
⁹ Hautarztpraxis Lübeck, Lübeck, Germany.
¹⁰ Dermatological Sciences, University of Manchester, Manchester, U.K.

No abstract available

References

1. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21:399-408.
1. Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165:1109-17.
1. Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586-96.
1. Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528-53.
1. Stamp LK, Barclay ML, O'Donnell JL et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2540-7.